USD 7.46
↑ 0.18 (2.47%)
| ticker | 1 day return % | 1 week return % | 1 month return % | 3 months return % | 6 months return % | 1 year return % | 3 years return % | 5 years return % | 10 years return % | maximum return % |
|---|---|---|---|---|---|---|---|---|---|---|
| RLFTF | 2.5 | 14.8 | 15.7 | 452.6 | 425.4 | 255.2 | -73.6 | -83.3 | -83.3 | -83.3 |
| S&P 500 | -1.3 | -1.8 | 1.0 | 5.9 | 10.6 | 30.4 | 25.4 | 88.1 | 187.6 | 33142.5 |
Our interactive price chart includes various drawing tools to help you analyze the product more effectively. Below is a quick guide on how to use these tools: Full Guideline
Feel free to experiment with these tools to enhance your technical analysis. Remember, any drawings you make are temporary and will be lost upon refreshing the page unless saved as an image using the 'Camera' icon.
Get instant AI-powered professional insights on prices:
💡Generate AI Technical Analysis ReportA Multi-Interval Candlestick Chart displays the price movements of an asset over different time intervals. Each candlestick represents the open, high, low, and close prices for a specific interval. The chart can be used to identify trends and patterns in price movements.
| Attribute | Value |
|---|---|
| symbol | RLFTF |
| name | Relief Therapeutics Holding AG |
| price | 7.46 |
| changes percentage | 2.47 |
| change | 0.18 |
| day low | 7.46 |
| day high | 7.46 |
| year high | 7.66 |
| year low | 1.10 |
| market cap | 93551399 |
| price avg 50 | 4.98 |
| price avg 200 | 2.35 |
| exchange | PNK |
| volume | 100 |
| avg volume | 3835 |
| open | 7.46 |
| previous close | 7.28 |
| eps | -4.10 |
| pe | -1.82 |
| earnings announcement | 2024-08-30T05:25:00.000+0000 |
| shares outstanding | 12540402 |
| timestamp | 2024-11-14 19:04:18 |
We derive the score of a company's financial statements by evaluating the weighted average sentiment across key within the statements. The cumulative score, normalized to a sum of 1, serves as a metric for assessing the company's performance during the specified period. A higher score indicates stronger performance. However, it's crucial to note that while this score provides valuable insights, it is just one of many factors to consider when making informed investment decisions. A holistic evaluation, considering various aspects of the company's financial health and market conditions, is essential for a well-rounded investment strategy.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001854078 | |||
| revenue | 6033000 | 6081000 | -0.79 |
| gross profit | 4297000 | -7562000 | 156.82 |
| gross profit ratio | 0.71 | -1.24 | 157.28 |
| research and development expenses | 1328000 | 12393000 | -89.28 |
| operating expenses | 9045000 | 29220000 | -69.05 |
| interest income | -461000 | 18000 | -2,661.11 |
| interest expense | 330000 | 156000 | 111.54 |
| ebitda | -108036000 | -49022000 | -120.38 |
| ebitdaratio | -17.91 | -4.05 | -341.62 |
| operating income | -110828000 | -52040000 | -112.97 |
| operating income ratio | -18.37 | -8.56 | -114.66 |
| net income | -98181000 | -50790000 | -93.31 |
| net income ratio | -16.27 | -8.35 | -94.85 |
| eps | -8.35 | -4.8 | -73.96 |
Revenue Growth: revenue decreased to 6 million in 2023 from 6 million in 2022 representing a change of -0.79%. This indicates a sales shrinking, which is a negative sign for the company.
Operating Expenses: Operating Expenses increased to 9 million in 2023 from 29 million in 2022 representing a change of -69.05%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) decreased to -108 million in 2023 from -49 million in 2022 representing a change of -120.38%. The decrease in EBITDA indicates declined operational efficiency and profitability.
Operating Income: Operating income decreased to -111 million in 2023 from -52 million in 2022 representing a change of -112.97%. The decrease in operating income indicates worse operational performance and decreased profitability.
Earnings per Share (EPS): EPS increased to -8.35 in 2023 from -8.35 in 2022 representing a change of -73.96%. This indicates that the company's earnings are decreasing and it is becoming less profitable on a per-share basis.
Gross Profit: Gross Profit increased to 4 million in 2023 from -8 million in 2022 representing a change of 156.82%. This indicates a sales profitability growth, which is a positive sign for the company.
Research and Development (R&D) Expenses: R&D Expenses increased to 1 million in 2023 from 12 million in 2022 representing a change of -89.28%. This shows that the company continues to invest in innovation and product development, which is crucial for long-term growth.
Net Income: Net income increased to -98 million in 2023 from -51 million in 2022 representing a change of -93.31%. The increase in net income shows improved profitability and indicates that the company is generating more profit for each dollar of revenue.
| 2024Q2 | 2024Q1 | Q/Q change % | |
|---|---|---|---|
| 0001854078 | |||
| revenue | 2827000 | 2827000 | 0.00 |
| gross profit | 2046000 | 2046000 | 0.00 |
| gross profit ratio | 0.72 | 0.72 | 0.00 |
| research and development expenses | 366500 | 366500 | 0.00 |
| operating expenses | 4035000 | 4035000 | 0.00 |
| interest income | 79000 | 0 | NaN |
| interest expense | 41000 | 0 | NaN |
| ebitda | -1270000 | -1270000 | 0.00 |
| ebitdaratio | -0.45 | -0.45 | 0.00 |
| operating income | -1989000 | -1989000 | 0.00 |
| operating income ratio | -0.7 | -0.7 | 0.00 |
| net income | -2278500 | -2278500 | 0.00 |
| net income ratio | -0.81 | -0.81 | 0.00 |
| eps | -0.18 | -0.18 | 0.00 |
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001854078 | |||
| total assets | 76390000 | 188798000 | -59.54 |
| total liabilities | 24162000 | 43381000 | -44.30 |
| total equity | 52228000 | 145417000 | -64.08 |
| cash and cash equivalents | 14556000 | 19237000 | -24.33 |
| short term investments | 9000 | 28000 | -67.86 |
| long term investments | 0 | 0 | NaN |
| total current assets | 18304000 | 22583000 | -18.95 |
| total non current assets | 58086000 | 166215000 | -65.05 |
| total current liabilities | 6909000 | 10716000 | -35.53 |
| total non current liabilities | 17253000 | 32665000 | -47.18 |
| common stock | 56163000 | 56163000 | 0.00 |
| retained earnings | -218264000 | -119599000 | -82.50 |
| total debt | 4311000 | 3064000 | 40.70 |
Total Assets: Total Assets decreased to 76 million in 2023 from 189 million in 2022 representing a change of -59.54%. Suggesting a decrease in asset holdings.
Total Equity: Total Equity decreased to 52 million in 2023 from 145 million in 2022 representing a change of -64.08%. This indicates a decrease in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 15 million in 2023 from 19 million in 2022 representing a change of -24.33%. This indicates a decrease in available liquid assets.
Short Term Investments: Short Term Investments decreased to 0 million in 2023 from 0 million in 2022 representing a change of -67.86%. This indicates a decrease in short-term investment holdings.
Total Current Assets: Total Current Assets decreased to 18 million in 2023 from 23 million in 2022 representing a change of -18.95%. This indicates a worsen liquidity position.
Retained Earnings: Retained Earnings decreased to -218 million in 2023 from -120 million in 2022 representing a change of -82.5%. This indicates an accumulated losses.
Total Debt: Total Debt increased to 4 million in 2023 from 3 million in 2022 representing a change of 40.7%. This indicates an increase in overall debt burden.
Total Liabilities: Total Liabilities decreased to 24 million in 2023 from 43 million in 2022 representing a change of -44.3%. This indicates a decrease in overall liabilities.
Total Current Liabilities: Total Current Liabilities decreased to 7 million in 2023 from 11 million in 2022 representing a change of -35.53%. This indicates a lower short-term debt burden.
| 2024Q2 | 2024Q1 | Q/Q change % | |
|---|---|---|---|
| 0001854078 | |||
| total assets | 70921000 | 70921000 | 0.00 |
| total liabilities | 21654000 | 21654000 | 0.00 |
| total equity | 49267000 | 49267000 | 0.00 |
| cash and cash equivalents | 10728000 | 10728000 | 0.00 |
| short term investments | 0 | 0 | NaN |
| long term investments | 0 | 0 | NaN |
| total current assets | 14711000 | 14711000 | 0.00 |
| total non current assets | 56210000 | 56210000 | 0.00 |
| total current liabilities | 4763000 | 4763000 | 0.00 |
| total non current liabilities | 16891000 | 16891000 | 0.00 |
| common stock | 1404000 | 1404000 | 0.00 |
| retained earnings | -222786000 | -222786000 | 0.00 |
| total debt | 2417000 | 12000 | 20,041.67 |
Total Debt: Total Debt increased to 2 million in 2024Q2 from 0 million in 2024Q1 representing a change of 20041.67%. This indicates an increase in overall debt burden.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001854078 | |||
| net change in cash | -4681000 | -25524000 | 81.66 |
| operating cash flow | -17612000 | -24126000 | 27.00 |
| free cash flow | -18058000 | -24647000 | 26.73 |
| capital expenditure | -446000 | -521000 | 14.40 |
| depreciation and amortization | 3318000 | 3860000 | -14.04 |
| deferred income tax | -13503000 | 22016000 | -161.33 |
| stock based compensation | 814000 | 2186000 | -62.76 |
| accounts payables | -599000 | -75000 | -698.67 |
| inventory | -330000 | 164000 | -301.22 |
| acquisitions net | 0 | -7920000 | 100.00 |
| investments in property plant and equipment | -446000 | -521000 | 14.40 |
| net cash used for investing activites | 8695000 | -7999000 | 208.70 |
| debt repayment | -550000 | -471000 | -16.77 |
| common stock issued | 5094000 | 7111000 | -28.36 |
| common stock repurchased | 0 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 4050000 | 6417000 | -36.89 |
| cash at end of period | 14556000 | 19237000 | -24.33 |
| accounts receivables | 129000 | -19000 | 778.95 |
| cash at beginning of period | 19237000 | 44761000 | -57.02 |
Net Change in Cash: Net Change in Cash increased to -5 million in 2023 from -26 million in 2022 representing a change of 81.66%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow increased to -18 million in 2023 from -24 million in 2022 representing a change of 27.0%. This indicates that the company generated more cash from its core business operations.
Free Cash Flow: Free Cash Flow increased to -18 million in 2023 from -25 million in 2022 representing a change of 26.73%. This indicates an increase in cash generated after accounting for capital expenditures.
Stock-Based Compensation: Stock-Based Compensation decreased to 1 million in 2023 from 2 million in 2022 representing a change of -62.76%. This indicates decreased expenses, which is generally considered a positive sign from a financial perspective.
Capital Expenditure: Capital Expenditure increased to 0 million in 2023 from -1 million in 2022 representing a change of 14.4%. This indicates an increase in the cash outflow required for acquiring or improving long-term assets.
Accounts Payables: The absolute value of Accounts Payables increased to 1 million in 2023 from 0 million in 2022 representing a change of -698.67%. This indicates that the company has increased its outstanding obligations to its suppliers.
Accounts Receivables: Accounts Receivables increased to 0 in 2023 from 0 million in 2022 representing a change of 778.95%. This suggests that the company is less capable of collecting payments from its customers.
| 2024Q2 | 2024Q1 | Q/Q change % | |
|---|---|---|---|
| 0001854078 | |||
| operating cash flow | -1583000 | -1583000 | 0.00 |
| free cash flow | -1669000 | -1583000 | -5.43 |
| capital expenditure | -86000 | 0 | NaN |
| depreciation and amortization | 719000 | 719000 | 0.00 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 0 | 0 | NaN |
| accounts receivables | 107000 | 107000 | 0.00 |
| accounts payables | 0 | 0 | NaN |
| inventory | 91500 | 91500 | 0.00 |
| acquisitions net | 0 | 0 | NaN |
| investments in property plant and equipment | 0 | 0 | NaN |
| net cash used for investing activites | -3500 | -3500 | 0.00 |
| debt repayment | 0 | 0 | NaN |
| common stock issued | 0 | 0 | NaN |
| common stock repurchased | 0 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | -308000 | -308000 | 0.00 |
| net change in cash | -3828000 | -1914000 | -100.00 |
| cash at end of period | 10728000 | -1914000 | 660.50 |
| cash at beginning of period | 14556000 | 0 | NaN |
Net Change in Cash: Net Change in Cash decreased to -4 million in 2024Q2 from -2 million in 2024Q1 representing a change of -100.0%. Indicating a declined ability to generate cash from the company's operations or its cash flow position.
Free Cash Flow: Free Cash Flow decreased to -2 million in 2024Q2 from -2 million in 2024Q1 representing a change of -5.43%. This indicates a decrease in cash generated after accounting for capital expenditures.
Capital Expenditure: Capital Expenditure decreased to 0 million in 2024Q2 from 0 million in 2024Q1 representing a change of nan%. This indicates a possible improved efficiency or a shift in the company's strategic priorities.
EPS represents the portion of a company's profit allocated to each outstanding share of common stock. A higher EPS is generally favorable, indicating stronger profitability on a per-share basis.
Positive EPS: A positive EPS signifies that a company is profitable, it is generally viewed positively, supporting stock value and investor confidence.
Negative EPS: Indicates that a company is operating at a loss, which could lead to negative sentiment, potential stock depreciation, and concerns about the company's financial health.
The Next Earning Date represents when the company plans to release its next set of financial results.
An upward trend in EPS suggests consistent growth in earnings, often leading to increased investor confidence. A downward trend may indicate a decline in earnings, potentially decreasing investor confidence and stock value. Fluctuating EPS suggests unpredictable financial performance, warranting cautious investor analysis.
Earnings surprise occurs when a company's actual earnings differ from analysts' expectations. A positive earnings surprise typically reflects better-than-expected performance, potentially leading to stock appreciation. Conversely, a negative earnings surprise can result in stock depreciation. An earnings surprise of zero means the earnings met expectations, which typically has a neutral impact on stock price.
Discover detailed analyst recommendations for stocks, including categories such as Buy, Hold, Sell, Strong Buy, and Strong Sell. These insights are based on thorough analysis of financial and market factors. The consensus is calculated by assigning a numerical score to each recommendation. These scores are then weighted and averaged over a specified period to provide a comprehensive view of the stock's outlook, with the final score determining the overall consensus.
| 2023-12-31 | 2022-12-31 | Y/Y change % | |
|---|---|---|---|
| FY | |||
| calendar year | 2023 | 2022 | NaN |
| revenue per share | 0.51 | 0.58 | -10.77 |
| net income per share | -8.35 | -4.8 | -73.86 |
| operating cash flow per share | -1.5 | -2.28 | 34.34 |
| free cash flow per share | -1.54 | -2.33 | 34.10 |
| cash per share | 1.24 | 1.82 | -32.00 |
| book value per share | 4.44 | 13.76 | -67.70 |
| tangible book value per share | -0.19 | -1.66 | 88.76 |
| shareholders equity per share | 4.44 | 13.76 | -67.70 |
| interest debt per share | 0.06 | 0.05 | 11.76 |
| market cap | 24010838.05 | 114487115.18 | -79.03 |
| enterprise value | 13765838.05 | 98314115.18 | -86.00 |
| pe ratio | -0.24 | -2.25 | 89.15 |
| price to sales ratio | 3.98 | 18.83 | -78.86 |
| pocfratio | -1.36 | -4.75 | 71.27 |
| pfcf ratio | -1.33 | -4.65 | 71.38 |
| pb ratio | 0.46 | 0.79 | -41.61 |
| ptb ratio | 0.46 | 0.79 | -41.61 |
| ev to sales | 2.28 | 16.17 | -85.89 |
| enterprise value over ebitda | -0.13 | -2.01 | 93.65 |
| ev to operating cash flow | -0.78 | -4.08 | 80.82 |
| ev to free cash flow | -0.76 | -3.99 | 80.89 |
| earnings yield | -4.09 | -0.44 | -821.72 |
| free cash flow yield | -0.75 | -0.22 | -249.35 |
| debt to equity | 0.01 | 0.0 | 148.29 |
| debt to assets | 0.0 | 0.0 | 120.40 |
| net debt to ebitda | 0.09 | 0.33 | -71.26 |
| current ratio | 2.65 | 2.11 | 25.71 |
| interest coverage | -335.84 | -333.59 | -0.68 |
| income quality | 0.18 | 0.48 | -62.24 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 2.86 | 1.27 | 124.17 |
| research and ddevelopement to revenue | 0.22 | 2.04 | -89.20 |
| intangibles to total assets | 0.71 | 0.86 | -17.45 |
| capex to operating cash flow | -0.03 | -0.02 | -17.27 |
| capex to revenue | 0.07 | 0.09 | -13.71 |
| capex to depreciation | 0.13 | 0.13 | -0.41 |
| stock based compensation to revenue | 0.13 | 0.36 | -62.47 |
| graham number | 28.9 | 38.57 | -25.06 |
| roic | -1.85 | -0.33 | -455.26 |
| return on tangible assets | -4.47 | -1.96 | -127.67 |
| graham net net | -0.61 | -2.13 | 71.22 |
| working capital | 11395000 | 11867000 | -3.98 |
| tangible asset value | -2186000 | -17498000 | 87.51 |
| net current asset value | -5858000 | -20798000 | 71.83 |
| invested capital | 68776000 | 177473000 | -61.25 |
| average receivables | 2440500 | 2395000 | 1.90 |
| average payables | 1324999.5 | 1662500 | -20.30 |
| average inventory | 392000 | 309000 | 26.86 |
| days sales outstanding | 171.64 | 122.69 | 39.90 |
| days payables outstanding | 215.51 | 43.47 | 395.71 |
| days of inventory on hand | 117.11 | 6.07 | 1,828.37 |
| receivables turnover | 2.13 | 2.98 | -28.52 |
| payables turnover | 1.69 | 8.4 | -79.83 |
| inventory turnover | 3.12 | 60.1 | -94.81 |
| roe | -1.88 | -0.35 | -438.22 |
| capex per share | 0.04 | 0.05 | -23.01 |
ROE: Return on Equity (ROE) decreased to -1.88 on 2023-12-31 from -0.35 on 2022-12-31, representing a change of -438.22%. Suggesting that the company has not been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio increased to -0.24 on 2023-12-31 from -2.25 on 2022-12-31, representing a change of 89.15%. Indicating an increase in the relative valuation of the company's stock.
Current Ratio: Current Ratio increased to 2.65 on 2023-12-31 from 2.11 on 2022-12-31, representing a change of 25.71%. The current ratio has been increasing, suggesting an increase in the company's short-term liquidity. Also, it's above 1, indicating the ability to cover short-term obligations.
Debt-to-Equity Ratio: Debt-to-Equity Ratio increased to 0.01 on 2023-12-31 from 0.00 on 2022-12-31, representing a change of 148.29%. The debt-to-equity ratio has been increasing, indicating that the company has been relying more on debt financing. Higher leverage may increase financial risk. However, a ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
| 2024-06-30 Q2 | 2024-03-31 Q1 | Q/Q change % | |
|---|---|---|---|
| RLFTF | |||
| calendar year | 2024 | 2024 | NaN |
| revenue per share | 0.23 | 0.23 | 0.00 |
| net income per share | -0.18 | -0.18 | 0.00 |
| operating cash flow per share | -0.13 | -0.13 | 0.00 |
| free cash flow per share | -0.13 | -0.13 | -5.43 |
| cash per share | 0.85 | 0.85 | 0.00 |
| book value per share | 3.92 | 3.92 | 0.00 |
| tangible book value per share | -0.33 | -0.33 | 0.00 |
| shareholders equity per share | 3.92 | 3.92 | 0.00 |
| interest debt per share | 0.0 | 0.0 | 341.67 |
| market cap | 14907852.64 | 16347352.45 | -8.81 |
| enterprise value | 6596852.64 | 5631352.45 | 17.15 |
| pe ratio | -1.64 | -1.79 | 8.81 |
| price to sales ratio | 5.27 | 5.78 | -8.81 |
| pocfratio | -9.42 | -10.33 | 8.81 |
| pfcf ratio | -8.93 | -10.33 | 13.50 |
| pb ratio | 0.3 | 0.33 | -8.81 |
| ptb ratio | 0.3 | 0.33 | -8.81 |
| ev to sales | 2.33 | 1.99 | 17.15 |
| enterprise value over ebitda | -5.19 | -4.43 | -17.15 |
| ev to operating cash flow | -4.17 | -3.56 | -17.15 |
| ev to free cash flow | -3.95 | -3.56 | -11.11 |
| earnings yield | -0.15 | -0.14 | -9.66 |
| free cash flow yield | -0.11 | -0.1 | -15.61 |
| debt to equity | 0.0 | 0.0 | 0.00 |
| debt to assets | 0.0 | 0.0 | 0.00 |
| net debt to ebitda | 6.54 | 8.44 | -22.44 |
| current ratio | 3.09 | 3.09 | 0.00 |
| interest coverage | -48.51 | 0 | NaN |
| income quality | 0.69 | 0.69 | 0.00 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0.36 | 0.36 | 0.00 |
| research and ddevelopement to revenue | 0.13 | 0.13 | 0.00 |
| intangibles to total assets | 0.75 | 0.75 | 0.00 |
| capex to operating cash flow | -0.05 | 0 | NaN |
| capex to revenue | 0.03 | 0 | NaN |
| capex to depreciation | 0.12 | 0 | NaN |
| stock based compensation to revenue | 0 | 0 | NaN |
| graham number | 4.0 | 4.0 | 0.00 |
| roic | -0.05 | -0.05 | 0.00 |
| return on tangible assets | -0.13 | -0.13 | 0.00 |
| graham net net | -0.8 | -0.8 | 0.00 |
| working capital | 9948000 | 9948000 | 0.00 |
| tangible asset value | -4126000 | -4126000 | 0.00 |
| net current asset value | -6943000 | -6943000 | 0.00 |
| invested capital | 66042000 | 66042000 | 0.00 |
| average receivables | 964000 | 1900500 | -49.28 |
| average payables | 1291000 | 1158000 | 11.49 |
| average inventory | 374000 | 465500 | -19.66 |
| days sales outstanding | 30.69 | 30.69 | 0.00 |
| days payables outstanding | 148.77 | 148.77 | 0.00 |
| days of inventory on hand | 43.1 | 43.1 | 0.00 |
| receivables turnover | 2.93 | 2.93 | 0.00 |
| payables turnover | 0.6 | 0.6 | 0.00 |
| inventory turnover | 2.09 | 2.09 | 0.00 |
| roe | -0.05 | -0.05 | 0.00 |
| capex per share | 0.01 | 0 | NaN |
ROE: Return on Equity (ROE) decreased to -0.05 on 2024-06-30 Q2 from -0.05 on 2024-03-31 Q1, representing a change of 0.00%. Suggesting that the company has not been generating high returns for its shareholders.
Current Ratio: Current Ratio decreased to 3.09 on 2024-06-30 Q2 from 3.09 on 2024-03-31 Q1, representing a change of 0.00%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. Since it's above 3, indicating poor management of working capital.
PE Ratio: Price-to-Earnings (P/E) Ratio increased to -1.64 on 2024-06-30 Q2 from -1.79 on 2024-03-31 Q1, representing a change of 8.81%. Indicating an increase in the relative valuation of the company's stock.
Debt-to-Equity Ratio: Debt-to-Equity Ratio decreased to 0.00 on 2024-06-30 Q2 from 0.00 on 2024-03-31 Q1, representing a change of 0.00%. The debt-to-equity ratio has been decreasing, indicating that the company has been relying less on debt financing. A ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
None
| Market Capitalization | Enterprise Value | |
|---|---|---|
| Definition | The total market value of a company's outstanding shares | The total market value of a company, including its debt and other liabilities |
| Calculation | Current share price * Total number of outstanding shares | Market capitalization + Total debt - Cash and cash equivalents |
| Focus | Equity component of a company's value | Total economic value of a company |
| Usefulness | Assesses a company's size and growth potential based on investor sentiment | Provides a more comprehensive valuation that considers both equity and debt |
Analyzing dividends is a crucial aspect of investment evaluation, offering valuable insights into a company's financial health and its commitment to shareholder returns. Dividends represent a portion of a company's profits distributed to its shareholders, providing a steady income stream. We help you analyze dividends based on the indicators mentioned below:
• Investors often assess the average dividend amount, observing trends over time to gauge the company's stability and growth potential. A positive trend in average dividends indicates a consistent and potentially lucrative investment. Additionally, evaluating the trend of dividend increases provides insight into the company's financial strength and management's confidence in future earnings.
• Consistency in paying dividends is a reassuring sign, reflecting a company's reliability and commitment to shareholder value. For investors, dividends not only offer income but also contribute to the overall total return on investment.
• Companies with a history of regular and increasing dividends can attract income-focused investors seeking stable returns, making dividends a critical factor in building a well-rounded investment portfolio.
Interested in the overall sentiment for a particular period? Check out our news sentiment analysis tool.
Sentiment: Positive
Publish Date: 2024-11-11 01:20:00
GENEVA, SWITZERLAND / ACCESSWIRE / November 11, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced positive final results from its proof-of-concept, investigator-initiated clinical trial evaluating RLF-TD011 for the treatment of epidermolysis bullosa (EB), a rare genetic condition characterized by fragile skin and chronic wounds. The clinical trial evaluated the effects of RLF-TD011 on microbiome diversity in chronic and acute wounds in EB patients, focusing primarily on the most severe forms of the disease (junctional and dystrophic EB).
Sentiment: Positive
Publish Date: 2024-11-04 01:20:00
GENEVA, SWITZERLAND / ACCESSWIRE / November 4, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced it has signed a non-binding letter of intent (LOI) with Renexxion, Inc. (Renexxion), a privately-held U.S.-based clinical-stage biotechnology company specializing in gastrointestinal disorders therapies. The proposed reverse merger between Relief and Renexxion aims to create a combined entity with an expanded therapeutic pipeline addressing critical unmet healthcare needs worldwide.
Sentiment: Positive
Publish Date: 2024-10-21 01:20:00
GENEVA, SWITZERLAND / ACCESSWIRE / October 21, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today reported that the European Patent Office (EPO) has issued a Notice of Allowance under Rule 71(3) EPC for Relief's patent application No. 20737588.2, titled "Therapeutic Uses of Oxidizing Hypotonic Acid Solutions.
Sentiment: Positive
Publish Date: 2024-09-18 01:20:00
GENEVA, SWITZERLAND / ACCESSWIRE / September 18, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced that it has completed dosing in its proof-of-concept clinical study of RLF-OD032 for the treatment of phenylketonuria (PKU), a rare inherited disorder affecting phenylalanine metabolism. The primary objectives of the study include the comparison of RLF-OD032 to a currently marketed sapropterin dihydrochloride product, with a focus on bioavailability under fed and fasting conditions.
Sentiment: Positive
Publish Date: 2024-09-02 01:20:00
GENEVA, SWITZERLAND / ACCESSWIRE / September 2, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, announced today that interim data from its clinical trial evaluating PKU GOLIKE® will be presented at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium being held in Porto, Portugal. The Company-sponsored, randomized, crossover, controlled study was conducted by the Inherited Metabolic Disorders Unit at Birmingham Children's Hospital, UK.
Sentiment: Positive
Publish Date: 2024-08-30 01:25:00
RLF-TD011 investigator-initiated trial results for EB wound treatment anticipated in the coming weeks RLF-OD032 pilot PK study progresses with potential NDA filing by mid- to late 2025 Streamlined operations and CHF 15.1 million cash reserves expected to provide funding into at least 2026 GENEVA, SWITZERLAND / ACCESSWIRE / August 30, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today reported its financial results for the half-year ended June 30, 2024, and provided a corporate update. Relief provided updates on its key development programs and strategic initiatives, including RLF-TD011, a hypochlorous acid topical spray designed for the treatment of epidermolysis bullosa (EB), and RLF-OD032, a novel liquid formulation of sapropterin dihydrochloride for the management of phenylketonuria (PKU).
* The sentiment analysis presented is generated through an algorithm and may be subject to inaccuracies. Users are advised to corroborate key information and employ further analytical methods prior to making critical decisions.
Get instant AI-powered professional insights:
💡Generate AI Technical Analysis ReportUnderstand the chart below:
Interpret Technical Indicators
| Indicator | Bullish | Bearish |
|---|---|---|
| Price and EMA ⓘ | Price crosses above EMA | Price crosses below EMA |
| Short-Term vs Long-Term EMA ⓘ | Short EMA crosses above Long EMA | Short EMA crosses below Long EMA |
| Volume ⓘ | Increasing volume during price uptrend | Increasing volume during price downtrend |
| MACD ⓘ | MACD crosses above Signal Line | MACD crosses below Signal Line |
| RSI ⓘ | RSI is below 30 (oversold) and starts to rise above 30 | RSI is above 70 (overbought) and starts to decline below 70 |
| Candlestick Patterns ⓘ | Bullish candlestick patterns | Bearish candlestick patterns |
Copyright © 2024 Sirius Investors
All rights reserved
